☆ 4.7 Article

Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine

VACCINES (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia

Frederikus A. Klok et al.

Summary: In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were rapidly developed and introduced, leading to a major impact on the evolution of the disease. However, reports of rare side-effects such as vaccine-induced immune thrombotic thrombocytopenia (VITT) have emerged, requiring prompt testing and treatment with intravenous immunoglobulin and non-heparin anticoagulants.

LANCET HAEMATOLOGY (2022)

Add to Collection

Article Immunology

Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

Giulia Costanzo et al.

Summary: This is a case report of a 71-year-old Caucasian woman with Eosinophilic Granulomatosis with Polyangiitis (EGPA). She had been treated with Mepolizumab since 2019 and had a good clinical response. In December 2020, she had a mild COVID-19 and tested negative for SARS-CoV-2 infection in late January 2021. After receiving the first dose of mRNA BNT162b2 vaccine in April 2021, she experienced a relapse of EGPA with symptoms of myalgia, dyspnea and limb numbness.

VACCINES (2022)

Add to Collection

Article Immunology

SARS-COV-2 Infection, Vaccination, and Immune-Mediated Diseases: Results of a Single-Center Retrospective Study

Michele Maria Luchetti Gentiloni et al.

Summary: This observational study conducted during the COVID-19 pandemic evaluates the onset of clinical and laboratory immune manifestations related to COVID-19 or SARS-CoV-2 vaccination. The results suggest that the interaction between SARS-CoV-2 and the host may induce complex immune-mediated reactions, potentially caused by anti-spike antibodies, in both healthy individuals and IMD patients. Additionally, the study finds that the anti-SARS-CoV-2 antibodies generated by vaccination may cause clinical manifestations similar to well-defined IMDs in healthy subjects.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety

Ainsley Ryan Yan Bin Lee et al.

Summary: This study conducted a systematic review and meta-analysis on the efficacy of COVID-19 booster vaccines. The results showed that booster doses are effective in inducing seroconversion in non-responders and are not associated with major adverse events.

VACCINES (2022)

Add to Collection

Article Immunology

New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine

Emanuele Nappi et al.

Summary: Anti-SARS-CoV-2 vaccines are safe and effective, but there are reports suggesting that they may trigger or exacerbate immune-mediated diseases in predisposed individuals. We describe a case of a 63-year-old man who experienced symptoms of eosinophilic granulomatosis with polyangiitis (EGPA) after receiving the booster dose of the mRNA-1273 vaccine. The patient also had worsening asthma after previous vaccine shots. Our report suggests caution in administering additional vaccine doses to individuals who experienced an increase in disease severity following previous shots.

VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Recrudescence of severe polyneuropathy after receiving Pfizer-BioNTech COVID-19 vaccine in a patient with a history of eosinophilic granulomatosis with polyangiitis

Rahul Gill et al.

Summary: This case report describes the recurrence of polyneuropathy in a patient with remission of eosinophilic granulomatosis with polyangiitis (EGPA) after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine. Although causality between the vaccine and the neuropathy was not proven, a possible association was considered and the patient showed improvement with corticosteroid treatment.

BMJ CASE REPORTS (2022)

Add to Collection

Review Immunology

Autoimmune Rheumatic Disease Flares with Myocarditis Following COVID-19 mRNA Vaccination: A Case-Based Review

Yi Wye Lai et al.

Summary: This study reports on four cases of myocarditis in patients with autoimmune rheumatic diseases following COVID-19 mRNA vaccination and reviews the literature on post-vaccination myocarditis and ARD flares. In contrast to isolated myocarditis, these patients had myocarditis associated with ARD flares and required increased immunosuppression for resolution.

VACCINES (2022)

Add to Collection

Article Rheumatology

Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares

Francesco Carubbi et al.

Summary: This study retrospectively investigated patients who developed new-onset immune-mediated inflammatory diseases (IMIDs) or flares of known IMIDs within 30 days after receiving any dose of anti-SARS-CoV2 vaccine, and analyzed the potential relationships with demographic, clinical, and serological variables. The results showed that a portion of patients without previously diagnosed IMIDs developed new IMIDs after vaccination, while a significant portion of patients with known IMIDs were referred due to disease flare after vaccination.

RMD OPEN (2022)

Add to Collection

Article Immunology

Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination

Samy Hakroush et al.

Summary: Continuous monitoring of COVID-19 vaccine safety is crucial as vaccination programs expand worldwide, particularly in detecting rare adverse events associated with vaccination.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

Abdulla Watad et al.

Summary: Although temporally-associated with SARS-CoV-2 vaccination, new-onset or flare of immune-mediated diseases (IMDs) appear rare. Most cases are of moderate severity and responsive to therapy, although some severe flares occurred.

VACCINES (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine

Swathi Sangli et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Thrombosis After Vaccination With Messenger RNA-1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?

Allyson M. Pishko et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Hypereosinophilia: a rare cause of stroke and multiorgan dysfunction

Kapil L. Barbind et al.

Summary: Eosinophilia can be caused by various conditions, including hypereosinophilic syndrome (HES) which is a rare but potentially life-threatening disorder. Early diagnosis and treatment are crucial in preventing fatal outcomes.

BMJ CASE REPORTS (2021)

Add to Collection

Review Immunology

Vaccinations and Autoimmune Diseases

Bianca Olivieri et al.

Summary: Vaccines are important public health tools that save lives, but not completely risk-free. Although rare, there are associations between certain vaccines and adverse reactions like Guillain-Barre syndrome or thrombocytopenia. Epidemiological studies do not support the hypothesis that vaccines cause systemic autoimmune diseases. Close monitoring of new vaccine safety is ongoing.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Rheumatology

Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review

Jon Badiola et al.

RHEUMATOLOGY INTERNATIONAL (2019)

Add to Collection

Article Rheumatology

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis

Vitor Teixeira et al.

RMD OPEN (2019)

Add to Collection

Article Medicine, General & Internal

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Matthieu Groh et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

Waleed Ghanima et al.

LANCET (2015)

Add to Collection

Review Immunology

Eosinophilic granulomatosis with polyangiitis: an overview

Andrea Gioffredi et al.

FRONTIERS IN IMMUNOLOGY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.